hypericin has been researched along with Neoplasms in 41 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study whether formulation influences biodistribution, necrosis avidity and tumoricidal effects of the radioiodinated hypericin, a necrosis avid agent for a dual-targeting anticancer radiotherapy." | 7.80 | Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation. ( Alpizar, YA; Bauwens, M; Chen, F; Cona, MM; de Witte, P; Feng, Y; Li, J; Ni, Y; Oyen, R; Sun, Z; Talavera, K; Verbruggen, A; Zhang, J, 2014) |
| "In conclusion, NTRT improved the anticancer efficacy of VDT in rabbits with VX2 tumors." | 5.42 | Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models. ( Chen, F; Dai, X; Li, Y; Ni, Y; Shao, H; Sun, Z; Xu, K; Zhang, J, 2015) |
| "To study whether formulation influences biodistribution, necrosis avidity and tumoricidal effects of the radioiodinated hypericin, a necrosis avid agent for a dual-targeting anticancer radiotherapy." | 3.80 | Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation. ( Alpizar, YA; Bauwens, M; Chen, F; Cona, MM; de Witte, P; Feng, Y; Li, J; Ni, Y; Oyen, R; Sun, Z; Talavera, K; Verbruggen, A; Zhang, J, 2014) |
| "Hypericin is a prominent secondary metabolite mainly existing in genus Hypericum." | 3.01 | Hypericin: A natural anthraquinone as promising therapeutic agent. ( Ding, K; He, J; Li, XX; Pan, XG; Wu, JJ; Xia, CY; Xu, JK; Zhang, J; Zhang, WK, 2023) |
| "Hypericin is a polycyclic aromatic naphthodianthrone that occurs naturally." | 2.72 | Hypericin-mediated photodynamic therapy for the treatment of cancer: a review. ( Cruz, LJ; Dong, X; Fu, J; Gu, Z; Hao, Y; He, Y; Ni, J; Qu, C; Yin, X; You, L; Yu, Z; Zeng, Y; Zhang, Z, 2021) |
| "Hypericin (HY) is an interesting photosensitizer with dark activity and photodynamic therapy (PDT) effects via p53-independent pathway." | 2.44 | Potentiation of the photodynamic action of hypericin. ( Heng, PW; Olivo, M; Saw, CL, 2008) |
| "Hypericin is a naturally occurring substance found in the common St." | 2.43 | Hypericin--the facts about a controversial agent. ( Alth, G; Burner, U; Grünberger, W; Kubin, A; Wierrani, F, 2005) |
| "Hypericin is a naturally occurring secondary metabolite in plants of the Hypericum genus, with Hypericum perforatum (St." | 2.43 | Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. ( Kiesslich, T; Krammer, B; Plaetzer, K, 2006) |
| "Hypericin aggregates were confirmed by absorption spectra typical of aggregated hypericin and by its short fluorescence lifetime." | 1.91 | Effective transport of aggregated hypericin encapsulated in SBA-15 nanoporous silica particles for photodynamic therapy of cancer cells. ( Almáši, M; Benziane, A; Girman, V; Huntošová, V; Miklóšová, M; Pevná, V; Vámosi, G; Zauška, Ľ; Zeleňák, V, 2023) |
| " A marked decrease in the glutathione level of a majority of cells was observed after more toxic combination treatment." | 1.42 | Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status. ( Fedoročko, P; Jendželovská, Z; Jendželovský, R; Kovaľ, J; Kuchárová, B; Mikeš, J; Mikešová, L; Vargová, J, 2015) |
| "In conclusion, NTRT improved the anticancer efficacy of VDT in rabbits with VX2 tumors." | 1.42 | Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models. ( Chen, F; Dai, X; Li, Y; Ni, Y; Shao, H; Sun, Z; Xu, K; Zhang, J, 2015) |
| "Moreover, we found that a subset of cancer patients of various cancer-types indeed possessed CALRlow or CRTlow-tumours." | 1.42 | Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. ( Agostinis, P; de Witte, P; Elsen, S; Garg, AD; Krysko, DV; Vandenabeele, P, 2015) |
| "Autophagy-attenuated cancer cells displayed enhanced ecto-CALR induction following Hyp-PDT, which strongly correlated with their inability to clear oxidatively damaged proteins." | 1.39 | ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. ( Agostinis, P; Dudek, AM; Ferreira, GB; Garg, AD; Krysko, DV; Mathieu, C; Vandenabeele, P; Verfaillie, T, 2013) |
| "Hypericin was conjugated to biotin-ethylenediamine in a straightforward coupling method using n-hydroxysuccinimide and dicyclohexylcarbodiimide." | 1.38 | Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy. ( Bauwens, M; Bormans, G; de Witte, P; Marysael, T; Ni, Y; Rozenski, J, 2012) |
| "Here, we show that when cancer cells are treated with hypericin-based PDT (Hyp-PDT), they surface-expose both HSP70 and calreticulin (CRT)." | 1.38 | Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. ( Agostinis, P; Garg, AD; Krysko, DV; Vandenabeele, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (21.95) | 29.6817 |
| 2010's | 19 (46.34) | 24.3611 |
| 2020's | 13 (31.71) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 1 |
| Zhang, G | 1 |
| Xu, S | 1 |
| Song, Y | 1 |
| Liang, R | 1 |
| Wong, KH | 1 |
| Yang, Y | 1 |
| Duan, Y | 1 |
| Chen, M | 1 |
| Wu, JJ | 1 |
| Zhang, J | 3 |
| Xia, CY | 1 |
| Ding, K | 1 |
| Li, XX | 1 |
| Pan, XG | 1 |
| Xu, JK | 1 |
| He, J | 1 |
| Zhang, WK | 1 |
| Buľková, V | 1 |
| Vargová, J | 3 |
| Babinčák, M | 1 |
| Jendželovský, R | 3 |
| Zdráhal, Z | 1 |
| Roudnický, P | 1 |
| Košuth, J | 1 |
| Fedoročko, P | 3 |
| de Morais, FAP | 1 |
| Balbinot, RB | 1 |
| Bakoshi, ABK | 1 |
| Lazarin-Bidoia, D | 1 |
| da Silva Souza Campanholi, K | 1 |
| da Silva Junior, RC | 1 |
| Gonçalves, RS | 1 |
| Ueda-Nakamura, T | 1 |
| de Oliveira Silva, S | 1 |
| Caetano, W | 1 |
| Nakamura, CV | 1 |
| Pevná, V | 1 |
| Zauška, Ľ | 1 |
| Benziane, A | 1 |
| Vámosi, G | 1 |
| Girman, V | 1 |
| Miklóšová, M | 1 |
| Zeleňák, V | 1 |
| Huntošová, V | 2 |
| Almáši, M | 1 |
| Borghi-Pangoni, FB | 1 |
| Junqueira, MV | 1 |
| Bruschi, ML | 1 |
| Ke, Z | 1 |
| Xie, A | 1 |
| Chen, J | 2 |
| Zou, Z | 1 |
| Shen, L | 1 |
| Dai, Y | 1 |
| Zou, D | 1 |
| Han, X | 1 |
| Taratula, O | 2 |
| Xu, K | 2 |
| St Lorenz, A | 1 |
| Moses, A | 1 |
| Jahangiri, Y | 1 |
| Yu, G | 1 |
| Farsad, K | 1 |
| Teng, X | 1 |
| Li, F | 1 |
| Lu, C | 1 |
| Li, B | 1 |
| Verebová, V | 1 |
| Beneš, J | 1 |
| Staničová, J | 1 |
| Li, Y | 2 |
| Wang, S | 1 |
| Jiang, X | 1 |
| Wang, X | 1 |
| Zhou, X | 1 |
| Wan, L | 1 |
| Zhao, H | 1 |
| Zhou, Z | 1 |
| Gao, L | 1 |
| Huang, G | 1 |
| Ni, Y | 6 |
| He, X | 1 |
| Dong, X | 1 |
| Zeng, Y | 1 |
| Zhang, Z | 1 |
| Fu, J | 1 |
| You, L | 1 |
| He, Y | 1 |
| Hao, Y | 1 |
| Gu, Z | 1 |
| Yu, Z | 1 |
| Qu, C | 1 |
| Yin, X | 1 |
| Ni, J | 1 |
| Cruz, LJ | 1 |
| Mikeš, J | 2 |
| Mikešová, L | 2 |
| Kuchárová, B | 2 |
| Čulka, Ľ | 1 |
| Fedr, R | 1 |
| Remšík, J | 1 |
| Souček, K | 1 |
| Kozubík, A | 1 |
| Geng, C | 1 |
| Zhang, Y | 1 |
| Hidru, TH | 1 |
| Zhi, L | 1 |
| Tao, M | 1 |
| Zou, L | 1 |
| Chen, C | 1 |
| Li, H | 1 |
| Liu, Y | 2 |
| Garg, AD | 4 |
| Dudek, AM | 1 |
| Ferreira, GB | 1 |
| Verfaillie, T | 1 |
| Vandenabeele, P | 3 |
| Krysko, DV | 3 |
| Mathieu, C | 1 |
| Agostinis, P | 7 |
| Cona, MM | 2 |
| Alpizar, YA | 1 |
| Li, J | 1 |
| Bauwens, M | 2 |
| Feng, Y | 2 |
| Sun, Z | 2 |
| Chen, F | 2 |
| Talavera, K | 1 |
| de Witte, P | 5 |
| Verbruggen, A | 2 |
| Oyen, R | 2 |
| Barras, A | 1 |
| Boussekey, L | 1 |
| Courtade, E | 1 |
| Boukherroub, R | 1 |
| Koole, M | 1 |
| Jendželovská, Z | 1 |
| Kovaľ, J | 1 |
| Shao, H | 1 |
| Dai, X | 1 |
| Elsen, S | 1 |
| Saw, CL | 1 |
| Heng, PW | 1 |
| Olivo, M | 5 |
| Karioti, A | 1 |
| Bilia, AR | 1 |
| Ni, G | 1 |
| Chi, M | 1 |
| Marysael, T | 2 |
| Lerut, E | 1 |
| Barliya, T | 1 |
| Mandel, M | 1 |
| Livnat, T | 1 |
| Weinberger, D | 1 |
| Lavie, G | 1 |
| Fu, CY | 1 |
| Raghavan, V | 1 |
| Lau, WK | 1 |
| Bormans, G | 1 |
| Rozenski, J | 1 |
| Krammer, B | 2 |
| Verwanger, T | 1 |
| Buzova, D | 1 |
| Petrovajova, D | 1 |
| Kasak, P | 1 |
| Nadova, Z | 1 |
| Jancura, D | 1 |
| Sureau, F | 1 |
| Miskovsky, P | 1 |
| Ali, SM | 1 |
| Piette, J | 2 |
| Volanti, C | 1 |
| Vantieghem, A | 2 |
| Matroule, JY | 2 |
| Habraken, Y | 1 |
| Chin, W | 2 |
| Lau, W | 1 |
| Lay, SL | 1 |
| Wei, KK | 1 |
| Kubin, A | 1 |
| Wierrani, F | 1 |
| Burner, U | 1 |
| Alth, G | 1 |
| Grünberger, W | 1 |
| Kiesslich, T | 1 |
| Plaetzer, K | 1 |
| Kocanova, S | 1 |
| Buytaert, E | 1 |
| Golab, J | 1 |
| Merlevede, W | 1 |
| de Witte, PA | 1 |
15 reviews available for hypericin and Neoplasms
| Article | Year |
|---|---|
Recent advances of quinones as a privileged structure in drug discovery.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cell Line, Tumor; Communicable Diseases; Drug | 2021 |
Hypericin: A natural anthraquinone as promising therapeutic agent.
Topics: Anthracenes; Anthraquinones; Humans; Neoplasms; Photochemotherapy | 2023 |
Biophysical Characterization and Anticancer Activities of Photosensitive Phytoanthraquinones Represented by Hypericin and Its Model Compounds.
Topics: Animals; Anthracenes; Anthraquinones; Antineoplastic Agents; Humans; Neoplasms; Perylene; Photochemo | 2020 |
Hypericin-mediated photodynamic therapy for the treatment of cancer: a review.
Topics: Anthracenes; Antineoplastic Agents; Humans; Molecular Targeted Therapy; Neoplasms; Perylene; Photoch | 2021 |
Sonodynamic therapy: A potential treatment for atherosclerosis.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Atherosclerosis; Berberine; Cell Death; Chal | 2018 |
ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses.
Topics: Animals; Anthracenes; Autophagy; Cell Death; Endoplasmic Reticulum Stress; Humans; Immune System Phe | 2014 |
Potentiation of the photodynamic action of hypericin.
Topics: Adjuvants, Pharmaceutic; Animals; Anthracenes; Combined Modality Therapy; Humans; Neoplasms; Perylen | 2008 |
Hypericins as potential leads for new therapeutics.
Topics: Anthracenes; Anti-Infective Agents; Antidepressive Agents; Cell Survival; Humans; Hypericum; Neoplas | 2010 |
New frontier in hypericin-mediated diagnosis of cancer with current optical technologies.
Topics: Anthracenes; Diagnostic Imaging; Fluorescence; Humans; Neoplasms; Perylene; Photochemotherapy; Photo | 2012 |
Molecular response to hypericin-induced photodamage.
Topics: Animals; Anthracenes; Antineoplastic Agents; Humans; Neoplasms; Perylene; Photochemotherapy; Photose | 2012 |
Cell death and growth arrest in response to photodynamic therapy with membrane-bound photosensitizers.
Topics: Animals; Anthracenes; Apoptosis; Cell Division; Humans; Mitochondria; Neoplasms; Perylene; Photochem | 2003 |
Hypericin--the facts about a controversial agent.
Topics: Animals; Anthracenes; Austria; Cell Death; Humans; Molecular Structure; Neoplasms; Perylene; Photoch | 2005 |
Perylenequinones in photodynamic therapy: cellular versus vascular response.
Topics: Animals; Anthracenes; Apoptosis; Blood Vessels; Humans; Neoplasms; Perylene; Phenol; Photochemothera | 2006 |
Cellular mechanisms and prospective applications of hypericin in photodynamic therapy.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Humans; Hydrogen-Io | 2006 |
Hypericin in cancer treatment: more light on the way.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Cytochrome c Group; HeLa Cells; Humans; Hypericum; Mi | 2002 |
26 other studies available for hypericin and Neoplasms
| Article | Year |
|---|---|
ROS-responsive dexamethasone micelles normalize the tumor microenvironment enhancing hypericin in cancer photodynamic therapy.
Topics: Anthracenes; Cell Line, Tumor; Dexamethasone; Endothelial Cells; Micelles; Neoplasms; Perylene; Phot | 2022 |
New findings on the action of hypericin in hypoxic cancer cells with a focus on the modulation of side population cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Basic Helix-Loop-Helix Transcription Factor | 2023 |
Advanced theranostic nanoplatforms for hypericin delivery in the cancer treatment.
Topics: Anthracenes; Caco-2 Cells; Humans; Lipids; Neoplasms; Perylene; Photochemotherapy; Polymers; Precisi | 2023 |
Effective transport of aggregated hypericin encapsulated in SBA-15 nanoporous silica particles for photodynamic therapy of cancer cells.
Topics: Anthracenes; Nanopores; Neoplasms; Perylene; Photochemotherapy; Photosensitizing Agents; Silicon Dio | 2023 |
Physicochemical stability of bioadhesive thermoresponsive platforms for methylene blue and hypericin delivery in photodynamic therapy.
Topics: Acrylates; Adhesives; Anthracenes; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberati | 2020 |
Naturally available hypericin undergoes electron transfer for type I photodynamic and photothermal synergistic therapy.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Electrons; Female; HeLa Cells; Humans | 2020 |
Biodegradable Hypericin-Containing Nanoparticles for Necrosis Targeting and Fluorescence Imaging.
Topics: Animals; Anthracenes; Cell Line, Tumor; Female; Humans; Mice; Nanoparticles; Necrosis; Neoplasms; Op | 2020 |
Carbon dot-assisted luminescence of singlet oxygen: the generation dynamics but not the cumulative amount of singlet oxygen is responsible for the photodynamic therapy efficacy.
Topics: Animals; Anthracenes; Antineoplastic Agents; Carbon; Female; HeLa Cells; Humans; Imidazoles; Lumines | 2020 |
Preparation and validation of cyclodextrin-based excipients for radioiodinated hypericin applied in a targeted cancer radiotherapy.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Anthracenes; Cyclodextrins; Excipients; Humans; Neoplasms; Peryle | 2021 |
Hypericin affects cancer side populations via competitive inhibition of BCRP.
Topics: Aldehyde Dehydrogenase; Animals; Anthracenes; ATP Binding Cassette Transporter, Subfamily B, Member | 2018 |
ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death.
Topics: Adenosine Triphosphate; Anthracenes; Autophagy; Autophagy-Related Protein 5; Calreticulin; CD4-Posit | 2013 |
Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.
Topics: Animals; Anthracenes; Antineoplastic Agents; Chemistry, Pharmaceutical; Dimethyl Sulfoxide; Iodine R | 2014 |
Hypericin-loaded lipid nanocapsules for photodynamic cancer therapy in vitro.
Topics: Anthracenes; Cell Line; Cell Survival; Drug Carriers; HeLa Cells; Humans; Hypericum; Light; Lipids; | 2013 |
Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic.
Topics: Animals; Anthracenes; Female; Humans; Iodine Radioisotopes; Male; Neoplasms; Perylene; Radiation Dos | 2014 |
Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status.
Topics: Anthracenes; ATP-Binding Cassette Transporters; Caspase 3; Cell Death; Cell Line, Tumor; Drug Synerg | 2015 |
Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.
Topics: Animals; Anthracenes; Autoradiography; Disease Models, Animal; Iodine Radioisotopes; Necrosis; Neopl | 2015 |
Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Calreticulin; Cancer Vacc | 2015 |
The possible use of hypericin to overcome drug resistance in cancer treatment.
Topics: Anthracenes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochr | 2011 |
Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Mice; Mice, Inbred C3H; Necrosis; Neo | 2011 |
Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy.
Topics: Anthracenes; Antineoplastic Agents; Blotting, Western; Cathepsin B; Cell Hypoxia; Cell Line; Cell Li | 2011 |
Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy.
Topics: Animals; Anthracenes; Antineoplastic Agents; Avidin; Biotin; Biotinylation; Cell Line, Tumor; Contra | 2012 |
Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin.
Topics: Animals; Anthracenes; Anthracyclines; Apoptosis; Cell Line; Dendritic Cells; Hematoporphyrin Photora | 2012 |
Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells.
Topics: Anthracenes; Cell Line, Tumor; Dextrans; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interact | 2012 |
Bio-distribution and subcellular localization of Hypericin and its role in PDT induced apoptosis in cancer cells.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Colonic Neoplasms; Cytochrome c Group; Humans; Intrac | 2002 |
Photodynamic-induced vascular damage of the chick chorioallantoic membrane model using perylenequinones.
Topics: Animals; Anthracenes; Blood Vessels; Chickens; Chorioallantoic Membrane; Neoplasms; Perylene; Photoc | 2004 |
Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Enzyme Induction; Enzyme Inhibitors; Heme Oxygenase-1; Hum | 2007 |